OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Overman on Choosing Between Regorafenib and TAS-102 in CRC

March 28th 2020

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

March 28th 2020

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Dr. Antonarakis on PD-1/PD-L1 Monotherapy in Prostate Cancer

March 28th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Dr. Nagalla on Need for Timely Assays for DOACs in MPNs

March 27th 2020

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC

March 27th 2020

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Dr. Burke on the Ongoing First-MIND Trial With Tafasitamab in DLBCL

March 27th 2020

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

Dr. Viprakasit on the Results of the BELIEVE Trial With Luspatercept in Beta-Thalassemia

March 27th 2020

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Dr. Schuster on GO29781 Trial With Mosunetuzumab in NHL

March 27th 2020

Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2020

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

Dr. McKay on Rationale for Real-World Analysis of Radium-223 in mCRPC

March 27th 2020

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Dr. Freedland on Real-World Evidence Vs PREVAIL Trial in mCRPC

March 27th 2020

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Dr. Gomella on Screening Recommendations in Prostate Cancer

March 27th 2020

Leonard G. Gomella, MD, discusses recommendations for screening in prostate cancer.

Dr. Tagawa on Safety Profile of 225Ac-J591 in mCRPC

March 27th 2020

Scott T. Tagawa, MD, MS, discusses the safety profile of novel monoclonal antibody 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Grivas on the Role of Targeted Therapy in Prostate Cancer

March 27th 2020

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Dr. Nagalla on Aspirin Use During DOAC Treatment for MPNs

March 26th 2020

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.

Dr. Mizrahi on Optimal Sequencing in BRAF V600E-Mutant mCRC

March 26th 2020

Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.

Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

March 26th 2020

Tannaz Armaghany, MD, discusses the importance of NCI-MATCH trial in colorectal cancer.

Dr. Nelson on QOL Data From the BEACON CRC Trial in mCRC

March 26th 2020

Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.

Dr. Salani on Choosing Among IV, IP, and Dose-Dense Chemo Regimens in Ovarian Cancer

March 26th 2020

Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.

Dr. O'Malley on the State of Immunotherapy in Ovarian Cancer

March 26th 2020

David O’Malley, MD, discusses the state of immunotherapy in ovarian cancer.